Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AstraZeneca PLC (AZN : NSDQ)
 
 • Company Description   
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Number of Employees: 83,100

 
 • Price / Volume Information   
Yesterday's Closing Price: $66.21 Daily Weekly Monthly
20 Day Moving Average: 7,810,391 shares
Shares Outstanding: 3,098.84 (millions)
Market Capitalization: $205,174.22 (millions)
Beta: 0.45
52 Week High: $71.70
52 Week Low: $53.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.53% 10.08%
12 Week 9.29% 22.83%
Year To Date 13.66% 38.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS
-
CAMBRIDGE,X0 CB2 0AA
GBR
ph: 44-20-3749-5000
fax: 44-12-2335-2858
ir@astrazeneca.com http://www.astrazeneca.com
 
 • General Corporate Information   
Officers
Pascal Soriot - Chief Executive Officer
Leif Johansson - Chairman
Aradhana Sarin - Chief Financial Officer
Katarina Ageborg - Director
Jeff Pott - Director

Peer Information
AstraZeneca PLC (AGN.)
AstraZeneca PLC (ABBV)
AstraZeneca PLC (NVO)
AstraZeneca PLC (LLY)
AstraZeneca PLC (RHHBY)
AstraZeneca PLC (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 046353108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 3,098.84
Most Recent Split Date: 7.00 (2.00:1)
Beta: 0.45
Market Capitalization: $205,174.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.91%
Current Fiscal Quarter EPS Consensus Estimate: $0.78 Indicated Annual Dividend: $1.93
Current Fiscal Year EPS Consensus Estimate: $3.34 Payout Ratio: 0.69
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.02
Estmated Long-Term EPS Growth Rate: 16.22% Last Dividend Paid: 02/24/2022 - $0.96
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 19.85
Trailing 12 Months: 23.82
PEG Ratio: 1.22
Price Ratios
Price/Book: 5.22
Price/Cash Flow: 14.57
Price / Sales: 4.95
EPS Growth
vs. Year Ago Period: 17.28%
vs. Previous Quarter: 13.10%
Sales Growth
vs. Year Ago Period: 55.60%
vs. Previous Quarter: -5.17%
ROE
03/31/22 - 26.29
12/31/21 - 27.48
09/30/21 - 29.53
ROA
03/31/22 - 8.72
12/31/21 - 8.56
09/30/21 - 8.10
Current Ratio
03/31/22 - -
12/31/21 - 1.16
09/30/21 - 1.13
Quick Ratio
03/31/22 - -
12/31/21 - 0.76
09/30/21 - 0.68
Operating Margin
03/31/22 - 20.05
12/31/21 - 20.08
09/30/21 - 19.28
Net Margin
03/31/22 - -2.56
12/31/21 - 0.30
09/30/21 - 4.49
Pre-Tax Margin
03/31/22 - -
12/31/21 - -0.71
09/30/21 - 4.69
Book Value
03/31/22 - -
12/31/21 - 12.68
09/30/21 - 12.88
Inventory Turnover
03/31/22 - -
12/31/21 - 1.74
09/30/21 - 1.58
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.72
09/30/21 - 0.71
Debt-to-Capital
03/31/22 - -
12/31/21 - 41.73
09/30/21 - 41.41
 

Powered by Zacks Investment Research ©